Table 2 Study group characteristics—coexisting diseases.
Whole group (n = 4071) | Females | Males | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
All (n = 1888) | Survivors (n = 1739) | Nonsurvivors (n = 149) | P value | All (n = 2183) | Survivors (n = 1996) | Nonsurvivors (n = 187) | P value | Females vs. Males | ||
Arterial hypertension, n (%) | 2294 (56.4%) | 1049 (55.6%) | 890 (53.2%) | 159 (73.6%) | < 0.001 | 1245 (57.0%) | 1059 (55.6%) | 186 (66.9%) | < 0.001 | 0.35 |
Diabetes, n (%) | 989 (24.3%) | 451 (23.9%) | 369 (22.1%) | 82 (38.0%) | < 0.001 | 538 (24.6%) | 439 (23.0%) | 99 (35.6%) | < 0.001 | 0.57 |
Asthma, n (%) | 253 (6.2%) | 170 (9.0%) | 151 (9.0%) | 19 (8.8%) | 0.91 | 83 (3.8%) | 74 (3.9%) | 9 (3.2%) | 0.60 | < 0.001 |
Chronic obstructive pulmonary disease, n (%) | 180 (4.4%) | 52 (2.8%) | 39 (2.3%) | 13 (6.0%) | 0.002 | 128 (5.9%) | 84 (4.4%) | 44 (15.8%) | < 0.001 | < 0.001 |
Heart failure, n (%) | 292 (7.2%) | 118 (6.3%) | 78 (4.7%) | 40 (18.5%) | < 0.001 | 174 (8.0%) | 109 (5.7%) | 65 (23.4%) | < 0.001 | 0.03 |
Hypercholesterolemia, n (%) | 841 (20.7%) | 368 (19.5%) | 305 (18.2%) | 63 (29.2%) | < 0.001 | 473 (21.7%) | 397 (20.8%) | 76 (27.3%) | 0.014 | 0.09 |
Atrial fibrillation, n (%) | 422 (10.4%) | 202 (10.7%) | 146 (8.7%) | 56 (25.9%) | < 0.001 | 220 (10.1%) | 161 (8.5%) | 59 (21.2%) | < 0.001 | 0.52 |
Stroke, n (%) | 268 (6.6%) | 133 (7.0%) | 94 (5.6%) | 39 (19.1%) | < 0.001 | 135 (6.2%) | 95 (5.0%) | 40 (14.4%) | < 0.001 | 0.27 |
Coronary artery disease, n (%) | 573 (14.1%) | 236 (12.5%) | 172 (10.3%) | 64 (29.6%) | < 0.001 | 337 (15.4%) | 248 (13.0%) | 89 (32.0%) | < 0.001 | 0.007 |
Myocardial infarction in history, n (%) | 296 (7.3%) | 101 (5.4%) | 68 (4.1%) | 33 (15.3%) | < 0.001 | 195 (8.9%) | 140 (7.4%) | 55 (19.8%) | < 0.001 | < 0.001 |
Chronic kidney disease, n (%) | 280 (6.9%) | 117 (6.2%) | 77 (4.6%) | 40 (18.5%) | < 0.001 | 163 (7.5%) | 128 (6.7%) | 35 (12.6%) | < 0.001 | 0.11 |
